Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board

NHS

News

<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during December 2019

December 2019

 

Formulary and Managed Entry Subgroup (FMESG)

18.12.19

The following FMESG actions for November 2019 have been proposed. We now seek comments on these proposals.  This consultation is open until 5pm on Wednesday 29th January.

18.12.19

The following FMESG actions for October 2019 have been proposed. We now seek comments on these proposals.  This consultation is open until 5pm on Wednesday 29th January 2020

Pathways and Guidelines Development Subgroup (PaGDSG)

19.12.19

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, an updated Greater Manchester wide guideline for prescribing infant formula for cow’s milk protein allergy in primary care is in development. We now seek comments on this draft. This consultation period is open until 5pm on Thursday 30th January 2020

18.12.19

Following GM-wide consultation and approval by PaGDSG, an updated ‘Neuropathic Pain in Adults- Guideline for Primary Care’  has been published.  The guideline has been updated to align with NICE CKS and NG173, with the exception that the previous recommendation of amitriptyline as the first line option has been retained. Relevant cautions regarding medicines and driving have been added, along with information reflecting the schedule change for pregabalin and gabapentin

17.12.19

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, an updated Greater Manchester-wide Shared Care Protocol for Melatonin in Children and Adolescents is in development. We now seek comments on this draft. This consultation is open until 5pm on 29th January.

17.12.19

Following GM-wide consultation and approval by PaGDSG, a new GMMMG  Insulin Prescribing Aid for Adults with Type 2 Diabetes has been published.

The guidance is intended for use by primary care, however some elements will also be relevant to secondary care.

It will support initiation and titration of insulin in adults with type 2 diabetes, in line with the GM formulary hierarchy of insulin choice and FMESG recommendations

17.12.19

Following GM-wide consultation and approval by PaGDSG, an updated  GMMMG Shared Care Protocol Riluzole for Amyotrophic Lateral Sclerosis has been published. The document has been updated to include the oral suspension.

17.12.19

Following GM-wide consultation and approval by PaGDSG, an updated  GMMMG Shared Care Protocol Paliperidone Long-acting antipsychotic injection has been published. The key change in the update is a simplification of monitoring requirements for primary care.

17.12.19

Following GM-wide consultation and approval by PaGDSG, a new GMMMG Shared Care Protocol Azathioprine for Autoimmune Hepatitis in Adults has been published
.

GMMMG

16.12.19

Following GM-wide consultation and approval by GMMMG, new GMMMG Guidance for Palliative Care Pain and Symptom Control in Adults has been published.  This guidance has been developed by the Greater Manchester and Eastern Cheshire Strategic Clinical Networks under the direction of PaGDSG, and is adopted for use by GMMMG. 

The guidance is for staff providing generalist palliative care in all settings, including primary and secondary care. It covers the management of symptoms and situations which palliative care patients may experience, as well as end of life care for patients with advanced progressive illness.

High Cost Drugs Subgroups

16.12.19

On behalf of the GMMMG HCD Groups, a Greater Manchester-wide commissioning statement for Andexanet alfa is in development. We now seek comments on this draft.

This consultation period is open until 5pm on Fri 24th Jan 2020

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer